Table 3.

Odds ratio (OR) and 95% confidence interval (CI) of treatment regimen for pathologic complete response stratified by stromal tumor-infiltrating lymphocytes

Cohort		Regimen	Multivariable analysis
			adjusted OR*	95% CI	P
All patients with sTILs	LPBC	Non-carboplatin	Ref.
		Carboplatin	1.01	0.31–3.26	0.986
		Pembrolizumab	6.40	1.09–37.47	0.040
	Non-LPBC	Non-carboplatin	Ref.
		Carboplatin	4.09	2.24–7.48	< 0.001
		Pembrolizumab	4.47	2.30–8.67	< 0.001
Cohort		Regimen	Multivariable analysis
			adjusted OR†	95% CI	P
cN + patients with sTILs	LPBC	Non-carboplatin	Ref.
		Carboplatin	0.98	0.30–3.23	0.977
		Pembrolizumab	11.45	1.17-112.43	0.036
	Non-LPBC	Non-carboplatin	Ref.
		Carboplatin	4.36	2.17–8.78	< 0.001
		Pembrolizumab	3.94	1.91–8.13	< 0.001

^*Adjusted for age (≤ 50 vs. > 50), histologic grade (1 vs. 2 vs. 3), clinical tumor stage (1 vs. 2 vs. 3 vs. 4), and clinical nodal stage (0 vs. 1 vs. 2 vs. 3). ^†Adjusted for age (≤ 50 vs. > 50), histologic grade (1 vs. 2 vs. 3), clinical tumor stage (1 vs. 2 vs. 3 vs. 4), and clinical nodal stage (1 vs. 2 vs. 3). sTILs, stromal tumor-infiltrating lymphocytes; LPBC, lymphocyte-predominant breast cancer. Supplemental Table 1. Baseline characteristics of patients according to neoadjuvant chemotherapy regimen with baseline sTIL values (n = 369)